Comparison of CYP2B6*6 and *1/*1 patients for specific posttreatment response indicators (means/frequencies) after FC
| . | *1/*1 . | *1/*6 and *6/*6 . | P value . |
|---|---|---|---|
| Hb (g/dL) | 12.6 | 13.1 | .302 |
| Platelets (× 109/L) | 122 | 148 | .037 |
| WBCs (× 109/L) | 3.8 | 4.2 | .001 |
| Lymphocytes (%) | 14.9 | 22.0 | .002 |
| Absolute lymphocytes (× 109/L) | 0.6 | 0.9 | .063 |
| Neutrophils (%) | 62 | 55.9 | .249 |
| Absolute neutrophils (× 109/L) | 2.0 | 2.3 | .224 |
| Lymph node enlargement | 8/72 (11.1%) | 11/40 (27.5%) | .036 |
| Liver enlargement | 11/71 (15.5%) | 2/39 (5.1%) | .132 |
| Spleen enlargement | 1/71 (1.4%) | 1/40 (2.5%) | > .999 |
| . | *1/*1 . | *1/*6 and *6/*6 . | P value . |
|---|---|---|---|
| Hb (g/dL) | 12.6 | 13.1 | .302 |
| Platelets (× 109/L) | 122 | 148 | .037 |
| WBCs (× 109/L) | 3.8 | 4.2 | .001 |
| Lymphocytes (%) | 14.9 | 22.0 | .002 |
| Absolute lymphocytes (× 109/L) | 0.6 | 0.9 | .063 |
| Neutrophils (%) | 62 | 55.9 | .249 |
| Absolute neutrophils (× 109/L) | 2.0 | 2.3 | .224 |
| Lymph node enlargement | 8/72 (11.1%) | 11/40 (27.5%) | .036 |
| Liver enlargement | 11/71 (15.5%) | 2/39 (5.1%) | .132 |
| Spleen enlargement | 1/71 (1.4%) | 1/40 (2.5%) | > .999 |
Hb, hemoglobin; WBC, white blood cells.